Suvretta's Prescription for Growth institutionalinvestor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from institutionalinvestor.com Daily Mail and Mail on Sunday newspapers.
Tibulizumab was licensed from Eli Lilly and Company on April 26, 2023
Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities. | June 6, 2023
Tibulizumab (ZB-106) was licensed from Eli Lilly and Company on April 26, 2023Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026SAN DIEGO (BUSINESS WIRE) $ZURA #TeamZura Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-as.
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.